RxDoctor Payments Data

Connie Soto

Family · Honolulu, HINPI 1124613922

Payments from drug & device makers

$837in general payments, 2019–2025

Across 16 payments — averaging $52.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$236
  • Heartflow, Inc.$166
  • Boehringer Ingelheim$153
  • Novo Nordisk$119
  • Medtronic$81
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$36
  • plus $45 from 2 others

What the payments were for

  • Food & beverage$75690%
  • Education$8110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$837 in reported general payments places this provider in the 70th percentile of 466 family providers in Hawaii.

See all family providers in Hawaii

Medicare billing

Part B allowed, 2024
$39,093
Medicare patients
185
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$72,544
EntrestoSacubitril/Valsartan18$19,469
XareltoRivaroxaban11$12,760
BrilintaTicagrelor13$11,350
Atorvastatin Calcium117$2,535
Metoprolol Succinate114$1,805
Ezetimibe20$1,212
Amlodipine Besylate72$913
ClopidogrelClopidogrel Bisulfate37$806
Losartan Potassium42$700
Rosuvastatin Calcium15$542
Carvedilol28$355
Metoprolol Tartrate23$281
Isosorbide Mononitrate ErIsosorbide Mononitrate20$256
Furosemide27$192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$72,54451 claims
Johnson & JohnsonXarelto$25$12,76011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 466 family providers in Hawaii.

Other family in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →